Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools.
Ivana AcimovicAleksandra ViloticMartin PeslAlain LacampagnePetr DvorakVladimir RotreklAlbano C MeliPublished in: BioMed research international (2014)
Human pluripotent stem cells (hPSCs), namely, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), with their ability of indefinite self-renewal and capability to differentiate into cell types derivatives of all three germ layers, represent a powerful research tool in developmental biology, for drug screening, disease modelling, and potentially cell replacement therapy. Efficient differentiation protocols that would result in the cell type of our interest are needed for maximal exploitation of these cells. In the present work, we aim at focusing on the protocols for differentiation of hPSCs into functional cardiomyocytes in vitro as well as achievements in the heart disease modelling and drug testing on the patient-specific iPSC-derived cardiomyocytes (iPSC-CMs).
Keyphrases
- induced pluripotent stem cells
- pluripotent stem cells
- replacement therapy
- embryonic stem cells
- single cell
- cell therapy
- endothelial cells
- pulmonary hypertension
- emergency department
- cell cycle arrest
- smoking cessation
- adverse drug
- cell death
- body composition
- mesenchymal stem cells
- signaling pathway
- high intensity
- pi k akt